Bowel cancer three-way test: Early screening saves lives
Colorectal cancer is one of the most common malignant tumors of the digestive system worldwide, and early diagnosis and treatment are essential to improve the survival rate of patients. However, because the early symptoms of bowel cancer are not obvious, many patients have progressed to the advanced stage by the time they are found, resulting in increased difficulty in treatment and greatly reduced survival rates. Therefore, the early screening of bowel cancer is particularly important.
In recent years, three combined detection projects of bowel cancer have attracted much attention. This project includes fecal calprotenin, fecal occult blood and transferrin detection, which can show better sensitivity and accuracy than a single method. A number of studies have confirmed that the concentration offecal calprotenin has a good correlation with intestinal inflammation, and the sensitivity and negative predictive value of the diagnosis of colorectal cancer are high. Fecal occult blood is a very useful diagnostic index for gastrointestinal bleeding, and is of great significance for the early screening of gastrointestinal malignancies (such as gastric cancer, colorectal cancer, polyps, adenomas). Elevated transferrin has also been linked to bowel cancer.
Statistics show that in 2020, there will be more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths from colorectal cancer worldwide. In 2040, the burden of colorectal cancer is projected to increase to 3.2 million new cases per year (a 63% increase) and 1.6 million deaths (a 73% increase). Early screening of bowel cancer can effectively reduce the mortality and improve the treatment effect. Therefore, early screening with three combined tests of bowel cancer is very important for early detection of patients and improvement of treatment effect.
In the current situation of international bowel cancer, we should be aware of the harm of bowel cancer, and actively participate in the early screening work of bowel cancer.Wizbiotech has independently developed three combined tests for bowel cancer as an efficient, safe and reliable early screening method that can help doctors detect patients earlier, improve treatment success and reduce mortality.If you are interested in our products, you can contact our sales!
